Download presentation
Presentation is loading. Please wait.
Published by현우 섭 Modified over 5 years ago
1
Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V. Scagliotti, MD, Dale Shuster, PhD, Sergey Orlov, PhD, Joachim von Pawel, MD, Frances A. Shepherd, MD, Jeffrey S. Ross, MD, Qiang Wang, PhD, Brian Schwartz, MD, Wallace Akerley, MD Journal of Thoracic Oncology Volume 13, Issue 6, Pages (June 2018) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Progression-free survival (PFS) (A) and overall survival (B) in patients with EGFR-mutant disease enrolled in the MARQUEE study. CI, confidence interval; HR, hazard ratio. Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.